Verona Pharma plc
VRNA
Clasificación en acciones
#2229
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Precio por acción
$106.91
Última sincronización: 2025-10-07
Capitalización bursátil
$9.09B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
GB
Comercio Verona Pharma plc (VRNA)
Categoría
Healthcare
Margen Operativo de Verona Pharma plc (VRNA)
Margen Operativo al October 2026 TTM: -365.73%
Según los informes financieros más recientes y el precio de las acciones de Verona Pharma plc, el margen operativo actual (TTM) es -365.73%. Al final de 2023, el margen operativo era 0.00%.
Historial de Margen Operativo de Verona Pharma plc desde 2005 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | -365.73% | 0.00% |
| 2024 | -365.73% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -14,435.81% | 7,776.37% |
| 2021 | -183.28% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -2,291,221.96% | 96.36% |
| 2018 | -1,166,819.68% | 53,319.21% |
| 2017 | -2,184.27% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -100.11% |
US
|
|
| -149.01% | -99.59% |
US
|
|
| 25.57% | -100.07% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.08% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.